Anticonvulsants Market Outlook
The global anticonvulsants market size was valued at USD 6.75 Billion in 2022 and is likely reach to USD 8.21 Billion by 2031, expanding at a CAGR of 2.2% during the forecast period, 2023–2031. The growth of the market is attributed to the high prevalence of patients across the world, increasing research of novel drugs, and rising awareness of the diseases around the globe.
Anticonvulsants drugs, also called as antiseizure or antiepileptic drugs, are types of medications used for the treatment based on symptoms of epileptic seizures. The epileptic seizures happen due to incorrect signal from the nerve cells to the brain or disturbance in the electrical activity of the brain, which results in recurring episodes.
Epilepsy can occur to people of different age groups due to some of these factors such as drug abuse and alcohol misuse, brain cancer, brain injury, and stroke.
The symptoms demonstrated by the patient before convulsions include nausea, strange feelings, visual loss, headache, numbness in the body parts, and the racing thoughts. Anticonvulsants drugs are also used as mood stabilizers as well as for the cure of neuropathic pain or bipolar disorders.
The anticonvulsant drugs work by controlling neuronal excitability through different molecular targets present at the synapse, such as glutamate receptors, voltage-gated ion channels, and voltage-gated GABA receptors. Orthodox antiepileptic drugs augment γ-aminobutyric acid (GABA) function or blocks sodium channels. Various antiepileptic drugs work on different or uncertain mechanisms of the action.
Some of the main anticonvulsant drugs in the market which are also used for pain management include depakote (divalproex), lyrica (pregabalin), topamax (topiramate), neurontin (gabapentin), and carbatrol/tegretol (carbamazepine).
Market Trends, Drivers, Restraints, and Opportunities
- High prevalence of epilepsy as well as rising awareness for the prevention of the disease among the population are driving the market in the coming future.
- Growing research & development activities for the advanced development in the epilepsy therapeutics is expected to propel the market expansion during the projected period.
- Inclining number of new drug approvals and favorable regulatory policies towards the development of new drugs are boosting the market. The perampanel and retigabine are newly approved antiepileptics.
- Increasing number of patent expiry of major drugs brand such as Lamictal is anticipated to restrict the market growth.
- Growing interest from government organizations providing information about disease management and spreading awareness of the disease are offering huge opportunities for market development.
Scope of Anticonvulsants Market Report
The report on the global anticonvulsants market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Anticonvulsants Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Products (Barbiturates, Aldehydes, Benzodiazepines, Aromatic Allylic Alcohols, Carboxamides, Bromides, Carbamates, Sulfonamides, Fructose Derivatives, Pyrrolidines, Triazines, Fatty Acids, Oxazolidinediones, Urea’s, GABA Analogs, Propionates, Hydantoins, Pyrimidinediones, Valproylamides, and Others), Applications (Epilepsy, Fibromyalgia, Migraine, Neuropathic Pain, Bipolar Disorder, Anxiety, and Borderline Personality Disorder), and End-users (Hospitals, Clinics, and Ambulatory Surgical Clinics)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
GlaxoSmithKline, Johnson & Johnson, Sanofi, Pfizer, Novartis, Abbott, Sunovion Pharmaceuticals, and Cephalon
Anticonvulsants Market Segment Insights
Barbiturates segment is expected to grow at a rapid pace
Based on products, the global anticonvulsants market is divided into barbiturates, aldehydes, triazines, benzodiazepines, aromatic allylic alcohols, bromides, carbamates, sulfonamides, pyrimidinediones, carboxamides, pyrrolidines, fatty acids, oxazolidinediones, urea’s, gaba analogs, propionates, fructose derivatives, hydantoins, valproylamides, and others.
The barbiturates segment is expected to grow at a rapid pace during the projected period owing to its high effectiveness and safety along with better tolerability. It is the first choice drug for the epilepsy patients and shows good effects against epilepsy.
The hydantoins segment, meanwhile, is anticipated to account for a considerable market share in the near future as they are modern anticonvulsants drugs and offer safety. Thus, the drugs are widely recommended by the healthcare professionals, which further boosts the segment growth.
Epilepsy segment is projected to expand at a considerable CAGR
On the basis of applications, the market is categorized as epilepsy, fibromyalgia, migraine, neuropathic pain, bipolar disorder, anxiety, and borderline personality disorder.
The epilepsy segment is projected to expand at a considerable CAGR during the forecast period owing to the large number of incidence of the disease and growing demand for effective drugs for the treatment from the patients. Additionally, increased awareness about the disease and development of novel drugs are boosting the market segment.
However, the neuropathic pain segment is expected to exhibit a robust growth rate during the targeted period due to the rising number of patients suffering from the disease and wide availability of the drugs for the disease treatment.
Clinics segment is anticipated to grow at a significant rate
Based on end-users, the global anticonvulsants market is segmented into hospitals, clinics, and ambulatory surgical clinics. The clinics segment is anticipated to grow at a significant rate in the coming years owing to large preference of patients towards clinics due to easy accessibility at low cost and expansion of specialized clinics for the particular disease treatment.
The patients can visit the clinics easily and get consultation of the doctor without going through the long process that are associated with patients’ visiting at the hospitals.
However, the hospitals segment is projected to exhibit lucrative growth during the forecast period as the patient with severe attack needs to find proper healthcare facility and high frequency of such patients visiting hospitals.
Anticonvulsants Market Regional Outlook
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the projected period due to the availability of high skilled healthcare professionals, extensive research activities, and high prevalence of epilepsy in the region.
The Asia Pacific market, on the other hand, is expected to propel at an impressive rate in the coming years due to the high number of targeted patients and rising number of patients who are awareness of the disease as well as treatment drugs. Moreover, several governments’ efforts in various countries for the disease management is anticipated to boost the regional market growth.
- Neuropathic Pain
- Bipolar Disorder
- Borderline Personality Disorder
- Ambulatory Surgical Clinics
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Johnson & Johnson
- Sunovion Pharmaceuticals
Key players competing in the global anticonvulsant market are GlaxoSmithKline; Johnson & Johnson; Sanofi; Pfizer; Novartis; Abbott; Sunovion Pharmaceuticals; and Cephalon.